Sichenzia Ross Ference Kesner LLP Represents MabVax Therapeutics Holdings, Inc. in $5 Million Registered Direct Offerings
Press Release – New York, NY – November 15, 2017 – Nationally recognized securities and corporate law firm Sichenzia Ross Ference Kesner LLP announced today that it has represented MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX), a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, in a series of registered direct offerings of common stock and preferred stock for aggregate gross proceeds of approximately $5,000,000.
The offerings were consummated in August, September and October 2017. The Sichenzia Ross Ference Kesner LLP team was led by partners Harvey Kesner, Avital Perlman and Tara Guarneri-Ferrara and associate Evan Berger.
Visit SRFK's LinkedIn page
Latest posts by Sichenzia Ross Ference Kesner LLP (see all)
- Sichenzia Ross Ference Kesner LLP Represents Rodman & Renshaw, a unit of H.C Wainwright, in a $3.9 Million Public Offering of Medical Transcript Billing, Corp. - December 11, 2017
- Happy Holidays from Sichenzia Ross Ference Kesner! - December 9, 2017
- Sichenzia Ross Ference Kesner LLP Represents Pareteum Corporation in $6.58 Million Registered Direct Offering and Concurrent Private Placement - December 6, 2017